LymphedemaV1, PascalFrancis, Corpus, bibRecord, 000235

Lymphaticovenular Bypass for Lymphedema Management in Breast Cancer Patients: A Prospective Study

Identifieur interne : 000235 ( PascalFrancis/Corpus ); précédent : 000234; suivant : 000236

Lymphaticovenular Bypass for Lymphedema Management in Breast Cancer Patients: A Prospective Study

Auteurs : David W. Chang

Source :

Plastic and reconstructive surgery : (1963) [ 0032-1052 ] ; 2010.

RBID : Pascal:10-0403998

Descripteurs français

Pascal (Inist)
- Lymphoedème, Cancer du sein, Dérivation, Traitement, Chirurgie, Conduite à tenir, Homme.

English descriptors

KwdEn :
- Breast cancer, Bypass, Clinical management, Human, Lymphedema, Surgery, Treatment.

Abstract

Background: Lymphedema is a common and debilitating condition. Management options for lymphedema are limited and controversial. The purpose of this prospective study was to provide a preliminary analysis of lymphaticovenular bypass for the treatment of upper limb lymphedema in breast cancer patients. Methods: Twenty patients with upper extremity lymphedema secondary to treatment of breast cancer underwent lymphaticovenular bypass using a "supermicrosurgical" approach. The mean age of the patients was 54 years, 16 patients had received preoperative radiation therapy, and all patients had received axillary lymph node dissection. The mean duration of lymphedema was 4.8 years, and the mean volume differential of the lymphedematous arm compared with the unaffected arm was 34 percent. Evaluation included qualitative assessment and quantitative volumetric analysis before surgery and at 1 month, 3 months, 6 months, and 1 year after the procedure. Results: The mean number of bypasses performed per patient was 3.5 (range, two to five), and the size of bypasses ranged from 0.3 to 0.8 mm. The mean operative time was 3.3 hours (range, 2 to 5 hours). Hospital stay was less than 24 hours for all patients. The mean follow-up time was 18 months. Nineteen patients (95 percent) reported symptom improvement following surgery, and 13 patients had quantitative improvement. The mean volume differential reduction was 29 percent at 1 month, 36 percent at 3 months, 39 percent at 6 months, and 35 percent at 1 year. No patients experienced postoperative complications or lymphedema exacerbation. Conclusions: Lymphaticovenular bypass may effectively reduce the severity of lymphedema in breast cancer patients. Long-term analysis is needed.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0032-1052`
A03		`1`		`@0 Plast. reconstr. surg. : (1963)`
A05				`@2 126`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 Lymphaticovenular Bypass for Lymphedema Management in Breast Cancer Patients: A Prospective Study`
A11	`01`	`1`		`@1 CHANG (David W.)`
A14	`01`			`@1 Department of Plastic Surgery, University of Texas M. D. Anderson Cancer Center @3 USA @Z 1 aut.`
A20				`@1 752-758`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 11075 @5 354000194183270030`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 47 ref.`
A47	`01`	`1`		`@0 10-0403998`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Plastic and reconstructive surgery : (1963)`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Background: Lymphedema is a common and debilitating condition. Management options for lymphedema are limited and controversial. The purpose of this prospective study was to provide a preliminary analysis of lymphaticovenular bypass for the treatment of upper limb lymphedema in breast cancer patients. Methods: Twenty patients with upper extremity lymphedema secondary to treatment of breast cancer underwent lymphaticovenular bypass using a "supermicrosurgical" approach. The mean age of the patients was 54 years, 16 patients had received preoperative radiation therapy, and all patients had received axillary lymph node dissection. The mean duration of lymphedema was 4.8 years, and the mean volume differential of the lymphedematous arm compared with the unaffected arm was 34 percent. Evaluation included qualitative assessment and quantitative volumetric analysis before surgery and at 1 month, 3 months, 6 months, and 1 year after the procedure. Results: The mean number of bypasses performed per patient was 3.5 (range, two to five), and the size of bypasses ranged from 0.3 to 0.8 mm. The mean operative time was 3.3 hours (range, 2 to 5 hours). Hospital stay was less than 24 hours for all patients. The mean follow-up time was 18 months. Nineteen patients (95 percent) reported symptom improvement following surgery, and 13 patients had quantitative improvement. The mean volume differential reduction was 29 percent at 1 month, 36 percent at 3 months, 39 percent at 6 months, and 35 percent at 1 year. No patients experienced postoperative complications or lymphedema exacerbation. Conclusions: Lymphaticovenular bypass may effectively reduce the severity of lymphedema in breast cancer patients. Long-term analysis is needed.
C02	`01`	`X`		`@0 002B25`
C02	`02`	`X`		`@0 002B12B04`
C02	`03`	`X`		`@0 002B20E02`
C03	`01`	`X`	`FRE`	`@0 Lymphoedème @5 01`
C03	`01`	`X`	`ENG`	`@0 Lymphedema @5 01`
C03	`01`	`X`	`SPA`	`@0 Linfedema @5 01`
C03	`02`	`X`	`FRE`	`@0 Cancer du sein @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Breast cancer @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Cáncer del pecho @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Dérivation @5 04`
C03	`03`	`X`	`ENG`	`@0 Bypass @5 04`
C03	`03`	`X`	`SPA`	`@0 Derivación @5 04`
C03	`04`	`X`	`FRE`	`@0 Traitement @5 05`
C03	`04`	`X`	`ENG`	`@0 Treatment @5 05`
C03	`04`	`X`	`SPA`	`@0 Tratamiento @5 05`
C03	`05`	`X`	`FRE`	`@0 Chirurgie @5 06`
C03	`05`	`X`	`ENG`	`@0 Surgery @5 06`
C03	`05`	`X`	`SPA`	`@0 Cirugía @5 06`
C03	`06`	`X`	`FRE`	`@0 Conduite à tenir @5 07`
C03	`06`	`X`	`ENG`	`@0 Clinical management @5 07`
C03	`06`	`X`	`SPA`	`@0 Actitud médica @5 07`
C03	`07`	`X`	`FRE`	`@0 Homme @5 08`
C03	`07`	`X`	`ENG`	`@0 Human @5 08`
C03	`07`	`X`	`SPA`	`@0 Hombre @5 08`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'appareil circulatoire @5 37`
C07	`01`	`X`	`ENG`	`@0 Cardiovascular disease @5 37`
C07	`01`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Pathologie des vaisseaux lymphatiques @5 38`
C07	`02`	`X`	`ENG`	`@0 Lymphatic vessel disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Linfático patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Tumeur maligne @2 NM @5 39`
C07	`03`	`X`	`ENG`	`@0 Malignant tumor @2 NM @5 39`
C07	`03`	`X`	`SPA`	`@0 Tumor maligno @2 NM @5 39`
C07	`04`	`X`	`FRE`	`@0 Cancer @2 NM`
C07	`04`	`X`	`ENG`	`@0 Cancer @2 NM`
C07	`04`	`X`	`SPA`	`@0 Cáncer @2 NM`
C07	`05`	`X`	`FRE`	`@0 Pathologie de la glande mammaire @2 NM @5 40`
C07	`05`	`X`	`ENG`	`@0 Mammary gland diseases @2 NM @5 40`
C07	`05`	`X`	`SPA`	`@0 Glándula mamaria patología @2 NM @5 40`
C07	`06`	`X`	`FRE`	`@0 Pathologie du sein @2 NM @5 41`
C07	`06`	`X`	`ENG`	`@0 Breast disease @2 NM @5 41`
C07	`06`	`X`	`SPA`	`@0 Seno patología @2 NM @5 41`
N21				`@1 263`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 10-0403998 INIST
ET :	Lymphaticovenular Bypass for Lymphedema Management in Breast Cancer Patients: A Prospective Study
AU :	CHANG (David W.)
AF :	Department of Plastic Surgery, University of Texas M. D. Anderson Cancer Center/Etats-Unis (1 aut.)
DT :	Publication en série; Niveau analytique
SO :	Plastic and reconstructive surgery : (1963); ISSN 0032-1052; Etats-Unis; Da. 2010; Vol. 126; No. 3; Pp. 752-758; Bibl. 47 ref.
LA :	Anglais
EA :	Background: Lymphedema is a common and debilitating condition. Management options for lymphedema are limited and controversial. The purpose of this prospective study was to provide a preliminary analysis of lymphaticovenular bypass for the treatment of upper limb lymphedema in breast cancer patients. Methods: Twenty patients with upper extremity lymphedema secondary to treatment of breast cancer underwent lymphaticovenular bypass using a "supermicrosurgical" approach. The mean age of the patients was 54 years, 16 patients had received preoperative radiation therapy, and all patients had received axillary lymph node dissection. The mean duration of lymphedema was 4.8 years, and the mean volume differential of the lymphedematous arm compared with the unaffected arm was 34 percent. Evaluation included qualitative assessment and quantitative volumetric analysis before surgery and at 1 month, 3 months, 6 months, and 1 year after the procedure. Results: The mean number of bypasses performed per patient was 3.5 (range, two to five), and the size of bypasses ranged from 0.3 to 0.8 mm. The mean operative time was 3.3 hours (range, 2 to 5 hours). Hospital stay was less than 24 hours for all patients. The mean follow-up time was 18 months. Nineteen patients (95 percent) reported symptom improvement following surgery, and 13 patients had quantitative improvement. The mean volume differential reduction was 29 percent at 1 month, 36 percent at 3 months, 39 percent at 6 months, and 35 percent at 1 year. No patients experienced postoperative complications or lymphedema exacerbation. Conclusions: Lymphaticovenular bypass may effectively reduce the severity of lymphedema in breast cancer patients. Long-term analysis is needed.
CC :	002B25; 002B12B04; 002B20E02
FD :	Lymphoedème; Cancer du sein; Dérivation; Traitement; Chirurgie; Conduite à tenir; Homme
FG :	Pathologie de l'appareil circulatoire; Pathologie des vaisseaux lymphatiques; Tumeur maligne; Cancer; Pathologie de la glande mammaire; Pathologie du sein
ED :	Lymphedema; Breast cancer; Bypass; Treatment; Surgery; Clinical management; Human
EG :	Cardiovascular disease; Lymphatic vessel disease; Malignant tumor; Cancer; Mammary gland diseases; Breast disease
SD :	Linfedema; Cáncer del pecho; Derivación; Tratamiento; Cirugía; Actitud médica; Hombre
LO :	INIST-11075.354000194183270030
ID :	10-0403998

Links to Exploration step

Pascal:10-0403998

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Lymphaticovenular Bypass for Lymphedema Management in Breast Cancer Patients: A Prospective Study</title>
<author><name sortKey="Chang, David W" sort="Chang, David W" uniqKey="Chang D" first="David W." last="Chang">David W. Chang</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Plastic Surgery, University of Texas M. D. Anderson Cancer Center</s1>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0403998</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0403998 INIST</idno>
<idno type="RBID">Pascal:10-0403998</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000235</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Lymphaticovenular Bypass for Lymphedema Management in Breast Cancer Patients: A Prospective Study</title>
<author><name sortKey="Chang, David W" sort="Chang, David W" uniqKey="Chang D" first="David W." last="Chang">David W. Chang</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Plastic Surgery, University of Texas M. D. Anderson Cancer Center</s1>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Plastic and reconstructive surgery : (1963)</title>
<title level="j" type="abbreviated">Plast. reconstr. surg. : (1963)</title>
<idno type="ISSN">0032-1052</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Plastic and reconstructive surgery : (1963)</title>
<title level="j" type="abbreviated">Plast. reconstr. surg. : (1963)</title>
<idno type="ISSN">0032-1052</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Breast cancer</term>
<term>Bypass</term>
<term>Clinical management</term>
<term>Human</term>
<term>Lymphedema</term>
<term>Surgery</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Lymphoedème</term>
<term>Cancer du sein</term>
<term>Dérivation</term>
<term>Traitement</term>
<term>Chirurgie</term>
<term>Conduite à tenir</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Lymphedema is a common and debilitating condition. Management options for lymphedema are limited and controversial. The purpose of this prospective study was to provide a preliminary analysis of lymphaticovenular bypass for the treatment of upper limb lymphedema in breast cancer patients. Methods: Twenty patients with upper extremity lymphedema secondary to treatment of breast cancer underwent lymphaticovenular bypass using a "supermicrosurgical" approach. The mean age of the patients was 54 years, 16 patients had received preoperative radiation therapy, and all patients had received axillary lymph node dissection. The mean duration of lymphedema was 4.8 years, and the mean volume differential of the lymphedematous arm compared with the unaffected arm was 34 percent. Evaluation included qualitative assessment and quantitative volumetric analysis before surgery and at 1 month, 3 months, 6 months, and 1 year after the procedure. Results: The mean number of bypasses performed per patient was 3.5 (range, two to five), and the size of bypasses ranged from 0.3 to 0.8 mm. The mean operative time was 3.3 hours (range, 2 to 5 hours). Hospital stay was less than 24 hours for all patients. The mean follow-up time was 18 months. Nineteen patients (95 percent) reported symptom improvement following surgery, and 13 patients had quantitative improvement. The mean volume differential reduction was 29 percent at 1 month, 36 percent at 3 months, 39 percent at 6 months, and 35 percent at 1 year. No patients experienced postoperative complications or lymphedema exacerbation. Conclusions: Lymphaticovenular bypass may effectively reduce the severity of lymphedema in breast cancer patients. Long-term analysis is needed.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0032-1052</s0>
</fA01>
<fA03 i2="1"><s0>Plast. reconstr. surg. : (1963)</s0>
</fA03>
<fA05><s2>126</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Lymphaticovenular Bypass for Lymphedema Management in Breast Cancer Patients: A Prospective Study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>CHANG (David W.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Plastic Surgery, University of Texas M. D. Anderson Cancer Center</s1>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA20><s1>752-758</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>11075</s2>
<s5>354000194183270030</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>47 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0403998</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Plastic and reconstructive surgery : (1963)</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background: Lymphedema is a common and debilitating condition. Management options for lymphedema are limited and controversial. The purpose of this prospective study was to provide a preliminary analysis of lymphaticovenular bypass for the treatment of upper limb lymphedema in breast cancer patients. Methods: Twenty patients with upper extremity lymphedema secondary to treatment of breast cancer underwent lymphaticovenular bypass using a "supermicrosurgical" approach. The mean age of the patients was 54 years, 16 patients had received preoperative radiation therapy, and all patients had received axillary lymph node dissection. The mean duration of lymphedema was 4.8 years, and the mean volume differential of the lymphedematous arm compared with the unaffected arm was 34 percent. Evaluation included qualitative assessment and quantitative volumetric analysis before surgery and at 1 month, 3 months, 6 months, and 1 year after the procedure. Results: The mean number of bypasses performed per patient was 3.5 (range, two to five), and the size of bypasses ranged from 0.3 to 0.8 mm. The mean operative time was 3.3 hours (range, 2 to 5 hours). Hospital stay was less than 24 hours for all patients. The mean follow-up time was 18 months. Nineteen patients (95 percent) reported symptom improvement following surgery, and 13 patients had quantitative improvement. The mean volume differential reduction was 29 percent at 1 month, 36 percent at 3 months, 39 percent at 6 months, and 35 percent at 1 year. No patients experienced postoperative complications or lymphedema exacerbation. Conclusions: Lymphaticovenular bypass may effectively reduce the severity of lymphedema in breast cancer patients. Long-term analysis is needed.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B25</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B12B04</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B20E02</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Lymphoedème</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Lymphedema</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Linfedema</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Cancer du sein</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Breast cancer</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Cáncer del pecho</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Dérivation</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Bypass</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Derivación</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Traitement</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Treatment</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Chirurgie</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Surgery</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Cirugía</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Conduite à tenir</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Clinical management</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Actitud médica</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Homme</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Human</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Hombre</s0>
<s5>08</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'appareil circulatoire</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Pathologie des vaisseaux lymphatiques</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Lymphatic vessel disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Linfático patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Cáncer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie de la glande mammaire</s0>
<s2>NM</s2>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Mammary gland diseases</s0>
<s2>NM</s2>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Glándula mamaria patología</s0>
<s2>NM</s2>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Pathologie du sein</s0>
<s2>NM</s2>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Breast disease</s0>
<s2>NM</s2>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Seno patología</s0>
<s2>NM</s2>
<s5>41</s5>
</fC07>
<fN21><s1>263</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 10-0403998 INIST</NO>
<ET>Lymphaticovenular Bypass for Lymphedema Management in Breast Cancer Patients: A Prospective Study</ET>
<AU>CHANG (David W.)</AU>
<AF>Department of Plastic Surgery, University of Texas M. D. Anderson Cancer Center/Etats-Unis (1 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Plastic and reconstructive surgery : (1963); ISSN 0032-1052; Etats-Unis; Da. 2010; Vol. 126; No. 3; Pp. 752-758; Bibl. 47 ref.</SO>
<LA>Anglais</LA>
<EA>Background: Lymphedema is a common and debilitating condition. Management options for lymphedema are limited and controversial. The purpose of this prospective study was to provide a preliminary analysis of lymphaticovenular bypass for the treatment of upper limb lymphedema in breast cancer patients. Methods: Twenty patients with upper extremity lymphedema secondary to treatment of breast cancer underwent lymphaticovenular bypass using a "supermicrosurgical" approach. The mean age of the patients was 54 years, 16 patients had received preoperative radiation therapy, and all patients had received axillary lymph node dissection. The mean duration of lymphedema was 4.8 years, and the mean volume differential of the lymphedematous arm compared with the unaffected arm was 34 percent. Evaluation included qualitative assessment and quantitative volumetric analysis before surgery and at 1 month, 3 months, 6 months, and 1 year after the procedure. Results: The mean number of bypasses performed per patient was 3.5 (range, two to five), and the size of bypasses ranged from 0.3 to 0.8 mm. The mean operative time was 3.3 hours (range, 2 to 5 hours). Hospital stay was less than 24 hours for all patients. The mean follow-up time was 18 months. Nineteen patients (95 percent) reported symptom improvement following surgery, and 13 patients had quantitative improvement. The mean volume differential reduction was 29 percent at 1 month, 36 percent at 3 months, 39 percent at 6 months, and 35 percent at 1 year. No patients experienced postoperative complications or lymphedema exacerbation. Conclusions: Lymphaticovenular bypass may effectively reduce the severity of lymphedema in breast cancer patients. Long-term analysis is needed.</EA>
<CC>002B25; 002B12B04; 002B20E02</CC>
<FD>Lymphoedème; Cancer du sein; Dérivation; Traitement; Chirurgie; Conduite à tenir; Homme</FD>
<FG>Pathologie de l'appareil circulatoire; Pathologie des vaisseaux lymphatiques; Tumeur maligne; Cancer; Pathologie de la glande mammaire; Pathologie du sein</FG>
<ED>Lymphedema; Breast cancer; Bypass; Treatment; Surgery; Clinical management; Human</ED>
<EG>Cardiovascular disease; Lymphatic vessel disease; Malignant tumor; Cancer; Mammary gland diseases; Breast disease</EG>
<SD>Linfedema; Cáncer del pecho; Derivación; Tratamiento; Cirugía; Actitud médica; Hombre</SD>
<LO>INIST-11075.354000194183270030</LO>
<ID>10-0403998</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000235 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000235 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:10-0403998
   |texte=   Lymphaticovenular Bypass for Lymphedema Management in Breast Cancer Patients: A Prospective Study
}}

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Lymphaticovenular Bypass for Lymphedema Management in Breast Cancer Patients: A Prospective Study

Lymphaticovenular Bypass for Lymphedema Management in Breast Cancer Patients: A Prospective Study

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri